Company intelligence / Profile preview

Cougar Sports

Los Angeles, California, United Stateswsucougars.com ↗

Ownership: Private
Development stage: Other

Overview

Cougar Biotechnology developed abiraterone acetate (CB7630), a small molecule inhibitor of 17-alpha-hydroxylase/C17,20 lyase for advanced prostate cancer. The drug showed promise in early clinical trials for hormone-refractory prostate cancer. Other assets included CB3304 for hematological malignancies and CB1089 for solid tumors.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Clinical collaborations with The Institute of Cancer Research and The Royal Marsden Hospital during development phase

Beyond the preview

Go deeper on Cougar Sports.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cougar Sports.

Explore the full profile